Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Unjha FormulationsBOM:531762 -2.41%72 Days Payable is 37.71 as of Mar. 2026, which is 23% below its 10-year median of 49.20. GuruFocus rates BOM:531762 with a GF Score™ of 72/100 and a GF Value™ of ₹23.14 (Fairly Valued). The stock has 2 warning signs investors should review. Among 925 Drug Manufacturers companies, Unjha Formulations ranks worse than 80.86% on this metric.
The historical rank and industry rank for Unjha Formulations's Days Payable or its related term are showing as below:
BOM:531762'
s Days Payable Range Over the Past 10 Years
Min: 29.89 Med: 49.2 Max: 80.67
Current: 43.44
During the past 13 years, Unjha Formulations's highest Days Payable was 80.67. The lowest was 29.89. And the median was 49.20.
BOM:531762's Days Payable is ranked worse than 80.86% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs BOM:531762: 43.44
Unjha Formulations's Days Payable
declined
from Mar. 2025 (45.95) to Mar. 2026 (37.71).
It may suggest that Unjha Formulationsaccelerated paying its suppliers.
Unjha Formulations Days Payable Related Terms
Unjha Formulations Days Payable Historical Data
* Premium members only.
The historical data trend for Unjha Formulations's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Unjha Formulations's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unjha Formulations Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unjha Formulations's Days Payable distribution charts can be found below:
* The bar in red indicates where Unjha Formulations's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Unjha Formulations's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unjha Formulations (BOM:531762) has a Days Payable of 37.71 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Unjha Formulations and its competitors. This is 23% below median its historical median of 49.20. Over the past decade, Unjha Formulations' Days Payable has ranged from 29.89 to 80.67. According to the industry distribution chart, Unjha Formulations ranks #748 out of 925 companies in the Drug Manufacturers industry, placing it in the top 80.9%.
Is Unjha Formulations' Days Payable too high?
Unjha Formulations' current Days Payable of 37.71 is 23% below median its 10-year median of 49.20. Over the past 10 years, this metric has ranged from a low of 29.89 to a high of 80.67. The Drug Manufacturers industry median Days Payable is 90.38. Unjha Formulations' value of 37.71 is 58.3% below this industry median. Based on the distribution chart, Unjha Formulations ranks #748 out of 925 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Unjha Formulations has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Unjha Formulations' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Unjha Formulations ranks #748 out of 925 companies for Days Payable. This places Unjha Formulations in the lower half of its industry. The industry median Days Payable is 90.38. Unjha Formulations' value of 37.71 is 58.3% below this benchmark. Historically, Unjha Formulations' own Days Payable has ranged from 29.89 to 80.67 over the past decade. While the company's 10-year median is 49.20 vs. the industry median of 90.38, Unjha Formulations has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Unjha Formulations's current Days Payable of 37.71 is 58.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Unjha Formulations and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unjha Formulations's current Days Payable is 37.71, which is 23% below median its own 10-year median of 49.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unjha Formulations stock overvalued right now?
Based on GuruFocus' analysis, Unjha Formulations (BOM:531762) is currently considered Fairly Valued. The stock's GF Value™ is ₹23.14, compared to a current price of ₹23.89 — trading 3.2% above its estimated fair value. The current Days Payable is 37.71, which is 23% below median its 10-year median of 49.20 and 58.3% below the Drug Manufacturers industry median of 90.38. Unjha Formulations' overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Unjha Formulations (BOM:531762), the current Days Payable is 37.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unjha Formulations (BOM:531762) Overvalued in 2026?
Based on GuruFocus' analysis, Unjha Formulations stock appears to be overvalued.
The current stock price of ₹23.89 is trading 3.2% above its estimated GF Value™ of ₹23.14.
GuruFocus considers Unjha Formulations to be Fairly Valued.
Key valuation signals for BOM:531762:
Days Payable: 37.71 (23% below median its 10-year median of 49.20)
GF Value™: ₹23.14 vs. price of ₹23.89 (3.2% above fair value)
Industry Position: 58.3% below the Drug Manufacturers median (#748 of 925)
No single metric tells the full story. See the BOM:531762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unjha Formulations Ltd is an India-based manufacturer and exporter of Ayurvedic products. The company products include Isabgol powder under the Fibron and Fibron SF name, and Sat-Isabgol and Isabgol Husk. It also offers human and veterinary medicines.
72GF Score
Get the complete analysis for BOM:531762
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531762 has been successfully added to your 
